In this episode of Topical Conversations, Naiem Issa, MD, and Christopher Bunick, MD, discuss their publication in the Journal of Drugs in Dermatology that highlighted a remarkable case of rapid plaque psoriasis clearance with bimekizumab. They explore the patient case, the mechanism of action driving the rapid response, key clinical insights, and future applications of bimekizumab in psoriatic arthritis (PsA) and hidradenitis suppurativa (HS).
Rapid clearance in a treatment-naïve patient
Dr Issa describes a male patient in his 30s with over 50% body surface area involvement who had classic plaque psoriasis but had been treatment-naïve for several years after moving to the US. After starting bimekizumab, the patient returned 3 days later, reporting rapid improvement, with plaques melting away and pruritus significantly improved within 24 hours.
By 72 hours, 90% of his body had cleared, and within a week, his skin was completely clear, with no residual itching. Dr Issa notes that such rapid improvement is rare with biologic therapies and highlights the potential for bimekizumab to dramatically alter disease progression and patient quality of life.
Dr Bunick emphasizes the underrecognized burden of itch in psoriasis, often associated more with atopic dermatitis than psoriasis, reflecting that bimekizumab’s efficacy in reducing both plaques and pruritus so quickly suggests it is a powerful option for improving patient outcomes.
Why does bimekizumab work so quickly?
Dr Bunick attributes bimekizumab’s rapid and sustained clearance to its unique mechanism of action. Unlike other IL-17 inhibitors, bimekizumab targets both IL-17A and IL-17F. While IL-17A is more potent, IL-17F is more abundant in psoriatic plaques, and inhibiting both cytokines leads to a stronger anti-inflammatory effect.
Dr Issa highlights head-to-head trials comparing bimekizumab to adalimumab, ustekinumab, and secukinumab, all of which demonstrated bimekizumab’s superior response rates at 4 weeks. Additionally, IL-17F inhibition has been linked to rapid transcriptional changes in psoriasis plaques, supporting the observed early clearance seen in clinical practice.
This challenges the traditional dogma that skin takes time to recover after inflammation subsides. Dr Bunick suggests that some patients may be capable of achieving near-immediate clearance, a paradigm shift in how dermatologists approach biologic response timelines.
Addressing safety concerns
Mood and suicidal ideation and behavior
While bimekizumab’s prescribing information includes a warning for suicidal ideation and behavior, Dr Issa notes that in pivotal trials, Patient Health Questionnaire-9 scores, which assess the degree of depression severity, tended to improve in patients treated with bimekizumab compared to placebo.
Dr Bunick compares this to oral isotretinoin, where concerns about depression often contrast with real-world improvements in patient mood and quality of life. As psoriasis improves, sleep, confidence, and social interactions also improve, often leading to better overall mental well-being.
Oral and corporal candidiasis
Candidiasis is the most common side effect associated with IL-17 inhibitors, but Dr Issa reassures that it is manageable with fluconazole or topical ketoconazole and rarely leads to treatment discontinuation.
Dr Bunick explains that oral candidiasis tends to occur once or twice in early treatment but does not persist in most patients. However, if candidiasis is recurrent, alternative treatments may be considered.
Expanding beyond psoriasis: bimekizumab in PsA and HS
With additional FDA approvals for PsA and HS, bimekizumab is positioned to expand its role in dermatology.
Dr Issa highlights that IL-17A and IL-17F levels are significantly elevated in HS, making bimekizumab a logical therapeutic option.
For PsA, Dr Bunick emphasizes the importance of dermatologists "owning" psoriatic arthritis—as experts in skin disease, dermatologists should be actively involved in joint disease management as well. Bimekizumab’s efficacy in both psoriasis and PsA provides an opportunity to optimize care for patients with both skin and joint involvement.
Positioning bimekizumab in the treatment landscape
With IL-23 inhibitors already used for PsA, dermatologists may be wondering how bimekizumab should be positioned within the treatment landscape.
Dr Bunick points to the ongoing BE BOLD trial, a direct head-to-head comparison of bimekizumab vs risankizumab in PsA, which will provide valuable insights into IL-17 vs IL-23 inhibition in psoriatic arthritis.
Key takeaways
In the first DermInsider - A Virtual Grand Rounds Series session of the year, join leading experts Dr. Bhutani and Dr. Serota for a dynamic deep dive into one of the most exciting frontiers in psoriatic disease management. Dr. Del Rosso moderates this 45-minute activity that explores the rapidly emerging role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their potential impact beyond metabolic disease. Don't miss out on this opportunity to catch up on breakthrough insights and emerging evidence on this hot topic!“We have some really interesting data on the horizon that’s going to hopefully help more providers feel confident about using [GLP-1] medications in conjunction with their psoriasis medications that they are used to using.” – Tina Bhutani, MD MASBest of FC25: GLP-1RAs in Psoriasis – Catching Up on The ScienceThis activity is supported by an educational grant from Lilly.
Got a few minutes? Join our expert faculty for their rapid-fire tips on getting started with GLP-1 receptor agonists for patients with psoriasis and obesity.“When we are treating patients with obesity and psoriasis in weight management, really focus on the health gains. It’s not about what people are losing, it’s about what they are gaining in this process.” – Angela Fitch, MDPlease visit the “Educational Resources” page to access the handouts developed by faculty on GLP's in psoriatic disease mentioned in this activity.This activity is supported by an educational grant from Lilly.
In this 20-minute Seminar in Depth from the 2025 Fall Clinical Dermatology Conference, the faculty explore what differentiates TYK2 inhibitors from traditional JAK inhibitors, as well as how to identify patients with psoriasis who may benefit from oral small molecule therapy.“When thinking about a medication, you need to take a number of things into consideration: location of disease, disease severity, and age. Age plays a big role when I think about what medication I’m going to choose for a patient – Are they of child-bearing age? Are they young and they live in group housing or a dorm?” – Benjamin Lockshin, MDFC25: Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis: An Online ActivityThis activity is supported by an educational grant from Bristol Myers Squibb.